文献速递心外重症与机械循环支持

新型磁悬浮心包内左心室辅助系统治疗晚期心衰:前瞻性多中心研究2年结果

A novel magnetically levitated intrapericardial left ventricular assist system in advanced heart failure-2-year results from a prospective, multi-centre study.
PubMed 文献 · Eur J Cardiothorac Surg · 2026-01-09

该研究在中国12个中心纳入50例晚期心衰患者,评估新型小型化磁悬浮连续流左心室辅助系统(Corheart 6)的长期疗效与安全性。2年无事件生存率为86%(95%CI 73.3%-94.2%),78%患者仍在设备支持中,主要不良事件包括右心衰、卒中、驱动线感染和消化道出血,无溶血或设备故障发生。

要点

  • 2年无事件生存率86%,78%患者维持设备支持
  • 卒中发生率6%,驱动线感染12%,右心衰4%
  • 无溶血及设备故障发生,安全性可接受

核心结论

  • Corheart 6左心室辅助系统在晚期心衰患者中显示出良好的长期有效性和安全性。

研究设计与样本

  • 前瞻性多中心临床研究,2022年1月至7月在中国12个中心纳入50例成人晚期心衰患者,左室射血分数<30%且心脏指数<2.0 L/min/m2。

主要发现

  • 2年随访时39例(78%)仍在设备支持中,3例(6%)接受心脏移植,1例(2%)因心脏恢复移除设备。
  • 2年无事件生存率为86%(95%CI 73.3%-94.2%)。
  • 主要不良事件包括右心衰2例(4%)、卒中3例(6%)、驱动线感染6例(12%)、消化道出血2例(4%)。
  • 无溶血或设备故障发生。

关键数值与推荐

  • 主要终点为2年生存(设备支持、移植或恢复)且无致残性卒中或设备更换的复合终点。
  • 入组标准为左室射血分数<30%且心脏指数<2.0 L/min/m2(无需正性肌力药或依赖持续静脉正性肌力药)。

临床怎么用

  • 该设备可作为晚期心衰患者长期循环支持的可行选择,需关注右心衰、卒中、驱动线感染和消化道出血等不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Left Ventricular Assist Devices have become an important therapy for advanced heart failure. We present 2-year results of the prospective, multicentre clinical trial in China, showing long-term efficacy and safety of a novel miniaturized magnetically levitated, continuous-flow left ventricular assist system. METHODS: Patients were adults with a left ventricular ejection fraction <30% and a cardiac index < 2.0 L/min/m2 without inotropic, or dependence on continuous intravenous inotropes. Clinical data, including survival status, laboratory parameters, adverse events, and functional status, were collected at baseline and at 3, 6, 12, and 24 months and analysed. The primary end-point was the composite of survival at 2 years (on device support, transplant, or recovery), free of disabling stroke or device replacement. RESULTS: A total of 50 patients were enrolled in 12 centres between January 2022 and July 2022. At the 2-year follow-up, 39 patients (78%) remained on device support, 3 patients (6%) received heart transplants, and 1 patient (2%) had the device explanted due to cardiac recovery. The 2-year event-free survival was 86% (95% Confidence Interval [CI]: 73.3% - 94.2%). Major adverse events included right heart failure (n = 2, 4%), stroke (n = 3, 6%), driveline infection (n = 6, 12%), and gastrointestinal bleeding (n = 2, 4%). No haemolysis or device malfunction occurred. CONCLUSIONS: This study demonstrates promising long-term effectiveness and safety of the Corheart 6 left ventricular assist system for circulatory support in patients with advanced heart failure.ClinicalTrials.gov: NCT05353816.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Wang X, Chen H, Du J, et al. A novel magnetically levitated intrapericardial left ventricular assist system in advanced heart failure-2-year results from a prospective, multi-centre study. Eur J Cardiothorac Surg. 2026. PMID: 41512307. doi:10.1093/ejcts/ezag014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。